Form 8-K - Current report:
SEC Accession No. 0000950170-25-069815
Filing Date
2025-05-13
Accepted
2025-05-13 07:56:19
Documents
13
Period of Report
2025-05-13
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K itos-20250513.htm   iXBRL 8-K 49115
2 EX-99.1 itos-ex99_1.htm EX-99.1 19747
3 GRAPHIC img229093814_0.jpg GRAPHIC 33113
  Complete submission text file 0000950170-25-069815.txt   234812

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itos-20250513.xsd EX-101.SCH 24894
15 EXTRACTED XBRL INSTANCE DOCUMENT itos-20250513_htm.xml XML 4704
Mailing Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472 857-204-4583
iTeos Therapeutics, Inc. (Filer) CIK: 0001808865 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39401 | Film No.: 25937203
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)